门诊氧疗改善纤维性间质性肺疾病患者生活质量(AmbOx 研究)
AmbOx 是一项前瞻性、开放标签、混合方法、交叉随机对照试验,在英国三个间质性肺疾病中心纳入静息不低氧、6 分钟步行试验中经皮血氧饱和度降至 88% 及以下的纤维性间质性肺疾病患者(共随机 84 例)。与不用氧相比,门诊氧疗 2 周显著改善 K-BILD 总分及呼吸困难与活动、胸部症状子域,心理子域无显著差异。
要点
- 静息不低氧但运动诱发低氧的纤维性 ILD 患者可考虑门诊氧疗。
核心结论
- 门诊氧疗似与孤立性运动性低氧的间质性肺疾病患者健康相关生活质量改善相关,可能是该类治疗选择有限患者的有效干预,但需进一步研究确认。
研究设计与样本
- 前瞻性、开放标签、混合方法、交叉随机对照试验,在英国三个间质性肺疾病中心开展,共随机 84 例,76 例完成试验。
主要发现
- 最常见不良事件为上呼吸道感染(氧疗组 3 例,无治疗组 1 例);发生 5 例严重不良事件,包括 2 例死亡(每组各 1 例),均认为与治疗无关。
关键数值与推荐
- 入选条件包括年龄 18 岁及以上、纤维性间质性肺疾病、静息不低氧,且筛查访视 6 分钟步行试验中经皮动脉血氧饱和度降至 88% 或以下。
临床怎么用
- 对静息不低氧但运动诱发明显低氧的纤维性间质性肺疾病患者,可评估门诊氧疗以改善生活质量相关结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In fibrotic interstitial lung diseases, exertional breathlessness is strongly linked to health-related quality of life (HRQOL). Breathlessness is often associated with oxygen desaturation, but few data about the use of ambulatory oxygen in patients with fibrotic interstitial lung disease are available. We aimed to assess the effects of ambulatory oxygen on HRQOL in patients with interstitial lung disease with isolated exertional hypoxia. METHODS: AmbOx was a prospective, open-label, mixed-method, crossover randomised controlled clinical trial done at three centres for interstitial lung disease in the UK. Eligible patients were aged 18 years or older, had fibrotic interstitial lung disease, were not hypoxic at rest but had a fall in transcutaneous arterial oxygen saturation to 88% or less on a screening visit 6-min walk test (6MWT), and had self-reported stable respiratory symptoms in the previous 2 weeks. Participants were randomly assigned (1:1) to either oxygen treatment or no oxygen treatment for 2 weeks, followed by crossover for another 2 weeks. Randomisation was by a computer-generated sequence of treatments randomly permuted in blocks of constant size (fixed size of ten). The primary outcome, which was assessed by intention to treat, was the change in total score on the King's Brief Interstitial Lung Disease questionnaire (K-BILD) after 2 weeks on oxygen compared with 2 weeks of no treatment. General linear models with treatment sequence as a fixed effect were used for analysis. Patient views were explored through semi-structured topic-guided interviews in a subgroup of participants. This study was registered with ClinicalTrials.gov, number NCT02286063, and is closed to new participants with all follow-up completed. FINDINGS: Between Sept 10, 2014, and Oct 5, 2016, 84 patients were randomly assigned, 41 randomised to ambulatory oxygen first and 43 to no oxygen. 76 participants completed the trial. Compared with no oxygen, ambulatory oxygen was associated with significant improvements in total K-BILD scores (mean 55·5 [SD 13·8] on oxygen vs 51·8 [13·6] on no oxygen, mean difference adjusted for order of treatment 3·7 [95% CI 1·8 to 5·6]; p<0·0001), and scores in breathlessness and activity (mean difference 8·6 [95% CI 4·7 to 12·5]; p<0·0001) and chest symptoms (7·6 [1·9 to 13·2]; p=0·009) subdomains. However, the effect on the psychological subdomain was not significant (2·4 [-0·6 to 5·5]; p=0·12). The most common adverse events were upper respiratory tract infections (three in the oxygen group and one in the no-treatment group). Five serious adverse events, including two deaths (one in each group) occurred, but none were considered to be related to treatment. INTERPRETATION: Ambulatory oxygen seemed to be associated with improved HRQOL in patients with interstitial lung disease with isolated exertional hypoxia and could be an effective intervention in this patient group, who have few therapeutic options. However, further studies are needed to confirm this finding. FUNDING: UK National Institute for Health Research.
引用
- Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018. PMID: 30170904. doi:10.1016/S2213-2600(18)30289-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。